MStranslate

17/12/2025

In disappointing news, the Phase 3 Sanofi trial of tolebrutinib in people living with primary progressive multiple sclerosis (PPMS) has not been successful. The company also announced that the U.S. Food and Drug Administration decision on tolebrutinib for non-relapsing secondary progressive MS (SPMS), which was expected before the end of 2025, has been delayed and is now expected by March 2026.

16/12/2025

MStranslate has officially reached 4,000 followers! Thank you to each and every one of you for trusting us as a source of reliable, accessible information about multiple sclerosis research. This community is what makes the page truly special. Your engagement, questions, encouragement and support mean the world to us. We’re so grateful to have you here and we look forward to continuing to share the latest in MS research with you.

15/12/2025

Being based in Australia, we were shocked and saddened by the events at Bondi Beach last night. Out of respect to those affected, we will not be posting our usual content today. To anyone in our community that is struggling with the traumatic news, Lifeline is providing ongoing support and can be contacted via the options show below.

11/12/2025

A defining feature of the ECTRIMS conference is its commitment to leaving a meaningful legacy for people living with multiple sclerosis in each host city. For 2025, Visit Barcelona, Esclerosis Múltiple España and the European Committee for Treatment & Research in Multiple Sclerosis have partnered to launch a new initiative focused on improving workplace conditions and supporting people with MS to remain in employment for longer.

A blog post by Barcelona Turisme, a Patient Community Day Supporting Partner, start the development of a project that will help people living with multiple sclerosis in their professional lives.

10/12/2025

New research from Oregon Health & Science University (OHSU) has identified a protein that may interfere with the body’s ability to make the cells needed for myelin repair. This protein, called CEMIP, could become an important new target for developing treatments aimed at promoting remyelination in people with multiple sclerosis.

08/12/2025

The European Committee for Treatment & Research in Multiple Sclerosis have just published the Impact Report from Patient Community Day 2025. This is a great opportunity to explore the key research highlights from the event and get insights from people throughout the MS community.

Since 2022, Patient Community Day (PCD) has grown from a modest beginning into a global legacy initiative uniting thousands of people living with MS, NMOSD, and MOGAD with the scientific community that serves them. What began as an advancement in accessibility and inclusion has become a recognised p...

05/12/2025

Mental health is such an important topic, but one we don't talk about often enough. Join Brett in this live broadcast and let's have an open and honest conversation about it!

04/12/2025

VOTE NOW: Since being diagnosed with multiple sclerosis, I have talked to a psychologist (react with LOVE for YES or WOW for NO)

03/12/2025

Today is International Day of People with Disability - Australia, a moment to recognise the strength, diversity and contributions of people living with disabilities – including those in our MS community. This year’s theme, “Fostering disability-inclusive societies for advancing social progress,” is a reminder that true progress in MS depends on inclusion: in research, in clinical trials, in care and in every conversation that shapes our future. By ensuring people with MS are heard, represented and empowered, we can drive better science, better support, and better outcomes for all. Thank you to everyone who helps make this page such a diverse, inclusive and supportive community.

28/11/2025

As the holidays approach, MS Australia have published their travel tips for people living with multiple sclerosis. What strategies do you use when you travel to make things easier and less stressful?

Travelling with MS can be incredibly rewarding, but it requires thoughtful preparation to ensure comfort, safety, and accessibility. With the right strategies, you can enjoy less stressful adventures and make the most of your journey.

26/11/2025

Researchers are launching a new trial of an mRNA vaccine targeting Epstein–Barr virus (EBV) to see whether it can help treat people with relapsing MS. Unlike traditional therapies that suppress the immune system, this vaccine aims to help the body better control EBV and potentially reduce MS activity.

The pharmaceutical company Moderna is launching a new trial to see if a vaccine against Epstein-Barr virus (EBV) can help treat people with relapsing MS.

25/11/2025

A new Canadian study, led by researchers at Dalhousie University, is exploring how both biological factors and social experiences influence outcomes for people living with MS. The project aims to better understand why some people face greater challenges than others and how care can be made more personalised and equitable. Importantly, it’s designed to include groups who have been under-represented in MS research.

Dalhousie researcher leads a $2M national study to explore how biological and social factors impact health outcomes for Canadians living with multiple sclerosis, aiming for more equitable care.